Tibet Rhodiola Pharmaceutical Holding Co. Financials

Market Capitalization CN¥11.51 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	15.60
Forward PE	8.59
Price to Sales TTM	CN¥3.91
Price to Book MRQ	CN¥3.17
Enterprise to Revenue	3.23
Enterprise to EBITDA	9.37

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	25.07%
Operating Margin	50.38%
Return on Assets TTM	12.63%
Return on Equity TTM	20.87%

Income Statement

Revenue TTM	CN¥2,941,761,792
Revenue per Share TTM	CN¥9.15
Quarterly Revenue Growth	2.40%
Gross Profit TTM	CN¥2,783,161,856
EBITDA	CN¥1,238,638,386
Net Income to Common TTM	CN¥737,439,040
Diluted EPS TTM	CN¥2.29
Quarterly Earnings Growth YoY	-35.00%

Balance Sheet

Total Cash MRQ	CN¥2,589,990,144
Total Cash per Share MRQ	CN¥8.04
Total Debt MRQ	CN¥
Total Debt to Equity MRQ	14.47
Current Ratio MRQ	3.58
Book Value per Share MRQ	CN¥11.26

Cash Flow

Operating Cash Flow TTM	CN¥1,027,399,296
Levered Free Cash Flow TTM	CN¥535,327,840

600211 Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	322,319,008
Float Shares	124,034,873
Avg 10 Volume	1,709,982
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	60.70%
% Held by Institutions	4.25%

Stock Price Summary

Beta	1.06
Fifty Two Week Low	CN¥31.23
Fifty Two Week High	CN¥47.88
Fifty Two Week Change	-19.49%
Day 50 MA	CN¥36.88
Day 200 MA	CN¥36.19

Dividends and Splits

Forward Annual Dividend Rate	CN¥1.05
Forward Annual Dividend Yield	2.93%
Trailing Annual Dividend Rate	CN¥0.26
Trailing Annual Dividend Yield	0.73%
Payout Ratio	66.85%
Dividend Date
Ex Dividend Date	2025-01-21
Last Split Factor
Last Split Date	2020-04-17